The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...
Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...
Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...
Things are going from bad to worse for the pharmaceutical giant.
Newsable Asianet News on MSN
PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug
In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results